atropine has been researched along with cp 154526 in 1 studies
Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (cp 154526) | Trials (cp 154526) | Recent Studies (post-2010) (cp 154526) |
---|---|---|---|---|---|
26,711 | 1,259 | 1,697 | 129 | 1 | 40 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arneric, SP; Bai, S; Clarke, T; Fitzgerald, L; Gilligan, PJ; Grossman, S; Hartig, P; He, L; Heman, K; Krause, C; Lelas, S; Li, YW; Marshall, A; McElroy, JF; Miller, K; Robertson, D; Saye, J; Trainor, G; Ward, K; Wong, H; Zaczek, R; Zeller, K; Zhang, G | 1 |
1 other study(ies) available for atropine and cp 154526
Article | Year |
---|---|
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
Topics: Administration, Oral; Animals; Behavior, Animal; Biological Availability; Clinical Trials as Topic; Dogs; Inhibitory Concentration 50; Rats; Receptors, Corticotropin-Releasing Hormone; Solubility; Structure-Activity Relationship; Triazines; Water | 2009 |